



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Corrigendum

Corrigendum to “Significance of interactions of BACE1–Arg235 with its ligands and design of BACE1 inhibitors with P₂ pyridine scaffold” [Bioorg. Med. Chem. Lett. 19 (2009) 2435]


Yoshio Hamada^a, Hiroko Ohta^a, Naoko Miyamoto^a, Diganta Sarma^a, Takashi Hamada^a, Tomoya Nakanishi^a, Moe Yamasaki^a, Abdellah Yamani^a, Shoichi Ishiura^b, Yoshiaki Kiso^{a,*}

^a Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science and 21st Century COE Program, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

^b Department of Life Sciences, Graduate School of Arts and Sciences, University of Tokyo, Meguro-ku, Tokyo 153-8902, Japan

The authors regret that Table 2 appeared incorrectly. The corrected table appears below.

Table 2
BACE1 inhibitory activities



Compound (KMI-No)	X	Y	BACE1 inhibition %		IC ₅₀ (nM)
			At 2 μM	At 0.2 μM	
KMI-1023	–H	–H	89	62	140
KMI-1036	–OSO ₂ CH ₃	–H	96	73	96
1 (KMI-1237)	–Cl	–H	98	87	22
2 (KMI-1256)	–Br	–H	99	88	15
3 (KMI-1293)	–I	–H	99	86	24
4 (KMI-1283)	–Cl	–F	99	91	13
5 (KMI-1303)	–Br	–F	99	93	9
6 (KMI-1302)	–I	–F	99	92	10

DOI of original article: [10.1016/j.bmcl.2009.03.049](https://doi.org/10.1016/j.bmcl.2009.03.049)

* Corresponding author. Tel.: +81 75 595 4635; fax: +81 75 591 9900.

E-mail address: kiso@mb.kyoto-phu.ac.jp (Y. Kiso).